Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
第三届董事会第二十一次会议决议公告
Regulatory Filings Classification · 85% confidence The document is an announcement of the board of directors’ meeting resolutions (third board, 21st meeting) detailing project approvals and vote results. It does not announce any changes in personnel (so not MANG), is not a shareholder vote declaration (not DVA), nor a formal financial report or investor presentation. It is a general regulatory announcement of board resolutions and thus falls into the miscellaneous Regulatory Filings category (RNS).
2026-05-27 Chinese
关于与杭州市钱塘区招商服务中心签订投资协议的公告
Regulatory Filings Classification · 48% confidence The document is a regulatory announcement by 康龙化成 (Beijing) New Drug Technology Co., Ltd. regarding the signing of an investment agreement with the Hangzhou Qiantang District Investment Service Center to build a new drug production and CDMO service base. It contains project details, board approval references, risk factors, and project background, but it is not a fundraising or financing update (no new debt or equity issuance), not an M&A or share transaction, and contains no financial statements or dividends. It is therefore a general regulatory disclosure that does not neatly fit into other specific categories, making it a Regulatory Filing (RNS).
2026-05-27 Chinese
关于投资建设年产200吨医药中间体及API项目的公告
Regulatory Filings Classification · 85% confidence The document is a formal exchange announcement by the board regarding an investment and construction project (200-ton API capacity). It contains risk warnings, project overview, approval references, and no substantive financial statements or fundraising details. It is not a standalone financial report, earnings release, management discussion, or securities issuance notice; instead it is a general regulatory disclosure to the exchange. Hence it falls under the Regulatory Filings (RNS) category.
2026-05-27 Chinese
关于追加认购投资基金份额的公告
Capital/Financing Update Classification · 93% confidence The document is a formal corporate announcement detailing Kanglong’s additional subscription of investment fund units and the structure of the funding arrangement. It describes a financing/investment transaction (capital deployment into a private equity fund) rather than financial results, board changes, or regulatory certification. This fits the Capital/Financing Update category.
2026-05-22 Chinese
独立董事候选人声明与承诺（李丽华）
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a formal statement and commitment from an independent director candidate (李丽华) of 康龙化成 (北京)新药技术股份有限公司, detailing her qualifications and compliance with relevant laws and stock exchange rules. This type of document is part of proxy materials provided to shareholders ahead of a general meeting to inform and solicit votes for board elections. It is not announcing an appointment (MANG) nor reporting voting results (DVA), but rather providing candidate information for voting. Therefore, it fits the Proxy Solicitation & Information Statement category (PSI).
2026-04-28 Chinese
独立董事提名人声明与承诺（曾劲峰）
Regulatory Filings Classification · 92% confidence The document is a formal announcement by the board nominating and making compliance statements for an independent director candidate under Shenzhen Stock Exchange rules. It contains no financials, voting results, or full meeting materials—it is a regulatory compliance filing of director nomination details. It does not itself effect a board change (MANG is for actual board changes), nor is it a proxy statement in full, so it falls under the general category of Regulatory Filings (RNS).
2026-04-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.